Shanghai Ruixing Genetic Technology

Shanghai Ruixing Genetic Technology is a China-based biotechnology company focused on the development of innovative gene therapies for rare and life-threatening genetic disorders. Established in 2021 by leading geneticists from Fudan University, the company utilizes a proprietary adeno-associated virus (AAV) vector platform to deliver functional genes to target tissues. Its primary research focus includes hematological and neuromuscular conditions, with lead programs targeting hemophilia B and spinal muscular atrophy. Ruixing Genetic emphasizes the optimization of vector design to enhance therapeutic expression while minimizing immunogenicity and off-target effects. The company has attracted significant investment from top-tier venture capital firms, supporting its transition from discovery to clinical-stage development. Through its integrated R&D approach, Ruixing Genetic aims to address the significant unmet medical needs of patients with genetic diseases in China and globally.